[Form 4] Palantir Technologies Inc. Insider Trading Activity

Rhea-AI Filing Summary

The Form 4 filed on 07/03/2025 reports routine equity-compensation activity by Forte Biosciences (FBRX) CEO, Chair and Director Paul A. Wagner. On 07/01/2025 he converted 1,250 restricted stock units into an equal number of common shares (code M) at a $0 exercise price. To cover statutory taxes, 98 shares were automatically surrendered (code F) at $12.44 each. Following the transactions, Wagner now owns 80,940 FBRX shares directly and retains 7,500 unvested RSUs.

No open-market buying or selling occurred, no cash changed hands, and the share count involved is immaterial relative to Forte’s public float, so market impact should be limited. Nevertheless, the filing incrementally increases insider ownership and signals that vesting under the 2021 Equity Incentive Plan continues as scheduled.

Positive

• Incremental increase in insider ownership: CEO now directly holds 80,940 shares, marginally improving management–shareholder alignment.

Negative

• None.

Insights

Securities Analyst

TL;DR: CEO exercised 1,250 RSUs, withheld 98 shares for taxes; ownership now 80,940 shares—neutral, routine vesting.

The transaction is a standard RSU conversion (code M) coupled with share withholding for taxes (code F). Dollar value is roughly $15k—far below any materiality threshold for Forte’s capitalization. Because there was no discretionary open-market purchase or sale, it neither signals bullishness nor concern. Insider ownership inches up, aligning incentives, but I judge the event non-impactful for valuation or liquidity.

Corporate Governance Expert

TL;DR: Filing shows scheduled vesting under 2021 plan; governance hygiene intact, no red flags.

The Form 4 confirms compensation mechanics: quarterly vesting of RSUs with automatic tax withholding. Such transparency supports good governance practices. The CEO still holds 7,500 unvested RSUs, maintaining performance alignment. There is no indication of accelerated vesting, pledging, or unusual derivative use. I classify the disclosure as neutral for governance risk assessments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moore Alexander D.

(Last) (First) (Middle)

C/O PALANTIR TECHNOLOGIES INC.

1200 17TH STREET, FLOOR 15

(Street)

DENVER CO 80202

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Palantir Technologies Inc. [ PLTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/01/2025		S(1)		2,400	D	$129.4035(2)	1,330,578	D
Class A Common Stock	07/01/2025		S(1)		10,700	D	$130.126(3)	1,319,878	D
Class A Common Stock	07/01/2025		S(1)		1,800	D	$131.159(4)	1,318,078	D
Class A Common Stock	07/01/2025		S(1)		1,000	D	$132.3948(5)	1,317,078	D
Class A Common Stock	07/01/2025		S(1)		2,100	D	$133.3964(6)	1,314,978	D
Class A Common Stock	07/01/2025		S(1)		1,300	D	$134.4485(7)	1,313,678	D
Class A Common Stock	07/01/2025		S(1)		600	D	$135.3017(8)	1,313,078	D
Class A Common Stock	07/01/2025		S(1)		100	D	$136.19	1,312,978	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person sold shares of Class A Common Stock in the open market pursuant to a Rule 10b5-1 trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), entered into on November 22, 2024.

2. This transaction represents sales executed in multiple open market sales. The sales reflected in this line item were made at prices ranging from $128.69 to $129.68. The price reported above reflects the weighted average sale price of trades occurring within that price range. See footnotes (3), (4), (5), (6), (7) and (8) for sales executed in other price ranges on the date indicated. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction represents sales executed in multiple open market sales. The sales reflected in this line item were made at prices ranging from $129.69 to $130.65. The price reported above reflects the weighted average sale price of trades occurring within that price range. See footnotes (2), (4), (5), (6), (7) and (8) for sales executed in other price ranges on the date indicated. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction represents sales executed in multiple open market sales. The sales reflected in this line item were made at prices ranging from $130.71 to $131.65. The price reported above reflects the weighted average sale price of trades occurring within that price range. See footnotes (2), (3), (5), (6), (7) and (8) for sales executed in other price ranges on the date indicated. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. This transaction represents sales executed in multiple open market sales. The sales reflected in this line item were made at prices ranging from $131.89 to $132.75. The price reported above reflects the weighted average sale price of trades occurring within that price range. See footnotes (2), (3), (4), (6), (7) and (8) for sales executed in other price ranges on the date indicated. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

6. This transaction represents sales executed in multiple open market sales. The sales reflected in this line item were made at prices ranging from $132.93 to $133.84. The price reported above reflects the weighted average sale price of trades occurring within that price range. See footnotes (2), (3), (4), (5), (7) and (8) for sales executed in other price ranges on the date indicated. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

7. This transaction represents sales executed in multiple open market sales. The sales reflected in this line item were made at prices ranging from $133.93 to $134.92. The price reported above reflects the weighted average sale price of trades occurring within that price range. See footnotes (2), (3), (4), (5), (6) and (8) for sales executed in other price ranges on the date indicated. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

8. This transaction represents sales executed in multiple open market sales. The sales reflected in this line item were made at prices ranging from $134.95 to $135.65. The price reported above reflects the weighted average sale price of trades occurring within that price range. See footnotes (2), (3), (4), (5), (6) and (7) for sales executed in other price ranges on the date indicated. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Remarks:

This Form 4 has been compiled based on applicable requirements to reflect the specific transactions described herein and is not intended to disclose or describe all shares and/or other equity securities owned or beneficially held by the Reporting Person. For additional details regarding the Reporting Person's overall stock and equity holdings, please see the Issuer's Proxy Statement filed with the Securities and Exchange Commission on April 25, 2025, including under the heading "Security Ownership Of Certain Beneficial Owners And Management" (subject to the definitions, explanations, and time periods described therein).

	/s/ Justin V. Laubach, under power of attorney	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Forte Biosciences (FBRX) report in the latest Form 4?

CEO Paul A. Wagner converted 1,250 RSUs into common stock and withheld 98 shares for taxes.

How many Forte Biosciences shares does the CEO own after the transaction?

He directly owns 80,940 shares and holds 7,500 unvested RSUs.

What are transaction codes M and F on Form 4?

M is an option/RSU conversion; F is a share disposal to satisfy tax withholding.

Was there an open-market sale or purchase of FBRX shares?

No, the activity was limited to RSU vesting and tax withholding—no cash sale or purchase.

Does the filing indicate any change to Forte Biosciences’ financial outlook?

No. The event is routine compensation vesting and does not affect the company’s operations or outlook.